Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this exciting learning session on managing Ph negative Acute lymphoblastic leukemia in adults.
Acute Lymphoblastic Leukemia (ALL) is a cancer of the blood and bone marrow that progresses rapidly without treatment. It can reoccur after being in remission from previous treatment. It has been noted that refractory ALL did not respond to treatment indicating the previous treatments did not kill enough leukemia cells (blasts) to reach complete remission.
Ph-positive ALL is a special type of ALL in which a genetic mutation is observed in the Philadelphia chromosome. In the case of Ph-negative ALL, genetic disparities are also observed and most importantly in Ph neg ALL there is a disproportionate survival rate among the patients.
Managing Ph neg ALL often becomes difficult, however, the procedures of management of Philadelphia chromosome (Ph)–negative acute lymphoblastic leukemia (ALL) have changed dramatically in recent years leading to a positive vibe for the situation.
Therefore, have overall knowledge regarding the management of Ph negative ALL. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Review looks at potential treatment targets in the tumor microenvironment.
3.
Even when they are not paying attention, children are still learning.
4.
The Benefits of Exercise for Substance Use Disorders.
5.
The top three drugs for multiple myeloma treatment upfront are four.
1.
The New Era of Oncology: Key Updates and Clinical Insights
2.
Everything You Need to Know About RDW-CV: A Comprehensive Guide
3.
Decoding Granular Cell Tumor: What You Need to Know
4.
Subchorionic Hematoma: Causes, Symptoms, and Treatment
5.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
2.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion
3.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Navigating the Complexities of Ph Negative ALL - Part XI
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation